Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock, down from their previous price target of $7.00.

PYXS has been the subject of a number of other research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Stephens initiated coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Stock Up 9.7 %

Shares of NASDAQ:PYXS opened at $1.69 on Friday. The firm has a market cap of $100.50 million, a P/E ratio of -1.64 and a beta of 1.00. Pyxis Oncology has a 12 month low of $1.49 and a 12 month high of $6.85. The company’s 50-day moving average price is $2.93 and its two-hundred day moving average price is $3.30.

Insider Activity

In other Pyxis Oncology news, CFO Pamela Ann Connealy acquired 88,850 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were acquired at an average price of $1.96 per share, with a total value of $174,146.00. Following the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pyxis Oncology

Several large investors have recently modified their holdings of the business. Blue Owl Capital Holdings LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at approximately $3,462,000. Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after buying an additional 743,499 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Pyxis Oncology during the third quarter worth $1,405,000. State Street Corp raised its holdings in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after acquiring an additional 208,344 shares during the period. Finally, abrdn plc lifted its position in Pyxis Oncology by 28.9% in the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock valued at $3,351,000 after acquiring an additional 204,742 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.